FeesSafety
Pluang+

HIVE Digital appoints Hubert Marleau as Independent Director of BUZZ HPC to strengthen AI infrastructure growth in Canada.

Company Fundamentals
15 Sep 2026
Newsfile Corp
View Source
Bullish
HIVE Digital appoints Hubert Marleau as Independent Director of BUZZ HPC to strengthen AI infrastructure growth in Canada.

HIVE Digital Technologies Ltd., through its subsidiary BUZZ High Performance Computing Inc. (BUZZ HPC), has appointed Canadian capital markets veteran Hubert Marleau as an Independent Director. Marleau brings over 50 years of experience in capital markets and governance, enhancing BUZZ HPC's board as it expands its sovereign AI infrastructure platform across Canada. This move aims to ensure disciplined governance and capital allocation as BUZZ HPC scales AI infrastructure in partnership with Bell. The company also highlighted its participation in ALL IN 2026, a major AI conference in Canada, where BUZZ HPC executives will discuss building responsible and sovereign AI infrastructure.

HIVE Digital Technologies Ltd.'s recent board appointment comes amid a mixed Technology sector performance on Pluang. For readers following the Technology sector, here is Pluang's market snapshot as of Sep 15, 2026 09:41 WIB: out of 150 priced US tech stocks, 79 rose and 70 fell. Notable movers include CRWD (Crowdstrike Holdings Inc) up 13.41%, PANW (Palo Alto Networks Inc) up 12.89%, and GLW (Corning Incorporated) down 12.81%.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
24 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App